What biomarker testing is recommended for locally advanced Prostate Cancer

Biomarker Testing for Locally Advanced Prostate Cancer

Based on the NCCN Guidelines, here's what's recommended for biomarker testing in locally advanced prostate cancer:

Standard Clinical Tools (Always Used)

Your doctor will start with these fundamental assessments:

• PSA level (prostate-specific antigen blood test)
• Gleason score (how aggressive the cancer cells look under a microscope)
• Grade Group (a classification system based on Gleason score)
• Clinical stage (how far the cancer has spread)

These basic tools help determine your risk category and guide initial treatment decisions.

Advanced Biomarker Testing (When Appropriate)

According to NCCN Guidelines, advanced biomarker tests should only be ordered when they have the potential to change your treatment plan—not routinely for everyone. Here are the key tests:

Multimodal Artificial Intelligence (MMAI) - Artera AI Prostate Test

• What it does: Uses digital pathology and artificial intelligence to analyze your tumor tissue
• Why it matters: Can predict whether you'll benefit from adding short-term hormone therapy (ADT) to radiation therapy
• Evidence: Validated in multiple large randomized clinical trials (NRG/RTOG studies)
• Clinical use: Helps distinguish patients who truly need combination therapy from those who may do well with radiation alone

22-Gene Genomic Classifier (Decipher)

• What it does: Analyzes gene expression patterns in your tumor tissue
• Why it matters: Provides prognostic information about risk of distant metastases (cancer spreading) and prostate cancer-specific mortality
• Evidence: Validated in post-radical prostatectomy settings and radiation therapy studies
• Important note: Not recommended for very-low-risk prostate cancer

Germline (Inherited) Genetic Testing

According to NCCN Guidelines, you should discuss germline testing if you have:

• A family history of cancer
• Certain genetic mutations that run in families (like BRCA1, BRCA2, or other DNA repair genes)

This identifies inherited cancer risk that could affect your family members and may influence treatment decisions.

Important Limitations

The NCCN Guidelines emphasize that many other biomarker tests exist (like Prolaris and Genomic Prostate Score), but they don't meet the highest level of evidence required for routine recommendation in locally advanced disease. This doesn't mean they're not useful—it means the evidence supporting them is still being developed.

Questions to Ask Your Oncologist

1. Based on my specific cancer characteristics, do you recommend any advanced biomarker testing?
2. How would these test results change my treatment plan?
3. Do I have any family history that would warrant germline genetic testing?
4. If I have biomarker testing, how long will results take, and how will you use them to guide my treatment?
5. Are there clinical trials available that use biomarker testing to guide treatment?

Key Principle

According to NCCN Guidelines, advanced biomarker tools should be used to improve shared decision-making between you and your care team—helping you understand your individual risk and make informed choices about treatment intensity. Your oncologist will determine which tests, if any, make sense for your specific situation.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.